MRG-006

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameMRG-006
Drug Alias Namerecombinant humanized IgG1 monoclonal antibody targeting human glypican-3 (GPC3) protein conjugated with exatecan via the MCC-AAQ linkerMRG-006AMRG-006
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Cleavable peptide linker
Mechanisms of ActionAnti-Glypican-3DNA topoisomerase I inhibitors
TargetsGlypican-3DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursLiver NeoplasmsCarcinoma, Hepatocellular +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Miracogen Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLepu Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLiver NeoplasmsCarcinoma, Hepatocellular +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A